X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs LUPIN LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA LUPIN LTD TORRENT PHARMA/
LUPIN LTD
 
P/E (TTM) x 36.3 148.6 24.4% View Chart
P/BV x 5.7 2.8 204.8% View Chart
Dividend Yield % 1.0 0.9 106.1%  

Financials

 TORRENT PHARMA   LUPIN LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
LUPIN LTD
Mar-17
TORRENT PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,7681,750 101.0%   
Low Rs1,1861,384 85.7%   
Sales per share (Unadj.) Rs346.1387.4 89.3%  
Earnings per share (Unadj.) Rs55.256.6 97.4%  
Cash flow per share (Unadj.) Rs73.376.8 95.4%  
Dividends per share (Unadj.) Rs14.007.50 186.7%  
Dividend yield (eoy) %0.90.5 198.0%  
Book value per share (Unadj.) Rs257.1298.9 86.0%  
Shares outstanding (eoy) m169.22451.58 37.5%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x4.34.0 105.5%   
Avg P/E ratio x26.827.7 96.8%  
P/CF ratio (eoy) x20.120.4 98.8%  
Price / Book Value ratio x5.75.2 109.6%  
Dividend payout %25.413.2 191.6%   
Avg Mkt Cap Rs m249,887707,513 35.3%   
No. of employees `00011.816.8 70.2%   
Total wages/salary Rs m9,93428,495 34.9%   
Avg. sales/employee Rs Th4,971.510,418.3 47.7%   
Avg. wages/employee Rs Th843.21,697.0 49.7%   
Avg. net profit/employee Rs Th792.41,523.0 52.0%   
INCOME DATA
Net Sales Rs m58,569174,943 33.5%  
Other income Rs m2,2331,065 209.7%   
Total revenues Rs m60,802176,008 34.5%   
Gross profit Rs m13,77344,931 30.7%  
Depreciation Rs m3,0699,122 33.6%   
Interest Rs m2,0561,525 134.8%   
Profit before tax Rs m10,88135,349 30.8%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5459,785 15.8%   
Profit after tax Rs m9,33625,575 36.5%  
Gross profit margin %23.525.7 91.6%  
Effective tax rate %14.227.7 51.3%   
Net profit margin %15.914.6 109.0%  
BALANCE SHEET DATA
Current assets Rs m53,841119,542 45.0%   
Current liabilities Rs m31,61261,206 51.6%   
Net working cap to sales %38.033.3 113.8%  
Current ratio x1.72.0 87.2%  
Inventory Days Days9776 127.9%  
Debtors Days Days8490 93.2%  
Net fixed assets Rs m42,079131,660 32.0%   
Share capital Rs m846903 93.7%   
"Free" reserves Rs m42,655134,073 31.8%   
Net worth Rs m43,501134,976 32.2%   
Long term debt Rs m22,40856,478 39.7%   
Total assets Rs m101,250266,073 38.1%  
Interest coverage x6.324.2 26.0%   
Debt to equity ratio x0.50.4 123.1%  
Sales to assets ratio x0.60.7 88.0%   
Return on assets %11.310.2 110.5%  
Return on equity %21.518.9 113.3%  
Return on capital %19.619.3 101.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m20,06681,885 24.5%   
Fx outflow Rs m5,30421,506 24.7%   
Net fx Rs m14,76260,378 24.4%   
CASH FLOW
From Operations Rs m10,12741,148 24.6%  
From Investments Rs m-7,869-25,287 31.1%  
From Financial Activity Rs m-1,9184,332 -44.3%  
Net Cashflow Rs m21220,193 1.0%  

Share Holding

Indian Promoters % 71.5 46.6 153.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 7.0 11.3 62.1%  
FIIs % 12.6 31.9 39.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.1 87.1%  
Shareholders   26,511 98,259 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  FDC LTD.  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  

Compare TORRENT PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; Pharma Stocks Witness Buying(12:30 pm)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the energy sector and pharma sector witnessing maximum buying interest.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)

Jul 4, 2018

The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jul 17, 2018 02:57 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS